Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

In Earnings Call, Hims CEO Addresses Scrutiny of GLP-1 Compounding

Hims & Hers faces a Novo Nordisk patent lawsuit and possible DOJ action after launching a copy of Wegovy, with stock down over 50% this year, company projects $2.7-$2.9 billion revenue.

Summary by STAT
Telehealth giant reports 2025 growth in revenue and subscribers, says 2026 weight loss business is "durable."

4 Articles

Seeking AlphaSeeking Alpha
Lean Right

Hims & Hers projects $2.7B–$2.9B revenue in 2026 while accelerating global expansion and new specialty launches (NYSE:HIMS)

Hims & Hers (HIMS) Q4 2025 earnings call recap: revenue, EBITDA, subscriber growth, new specialties, and international expansion outlook.

·United States
Read Full Article
STATSTAT
Center

In earnings call, Hims CEO addresses scrutiny of GLP-1 compounding

Telehealth giant reports 2025 growth in revenue and subscribers, says 2026 weight loss business is "durable."

·Boston, United States
Read Full Article
The Motley FoolThe Motley Fool
Lean Left

Hims & Hers (HIMS) Earnings Call Transcript

Hims & Hers (HIMS) Earnings Call Transcript

·Alexandria, United States
Read Full Article
sherwood.newssherwood.news
Lean Left

Hims reports Q4 earnings beat, revenue miss

The report comes as the company has faced mounting legal troubles related to its short-lived Wegovy pill copy....

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources lean Left
50% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

sherwood.news broke the news in on Monday, February 23, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Wegovy icon

Wegovy

GLP-1 icon

GLP-1

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal